Biz Break: Google to help make surgical robots, challenging Intuitive Surgical
By Jeremy C. Owens
Google stressed that the life sciences team at Google X will only be providing software and sensors for the proposed systems, with J&J's Ethicon unit handling the rest of work.. The Mountain View company's robotics arm -- Google acquired robotics firm Boston Dynamics in late 2013 -- will not be involved.
"We think we can use some of our machine vision and image analysis software to help surgeons see better as they operate (e.g. to highlight blood vessels) or make it easier for them to see information that's relevant to the surgery at just the right time"
Just wondering how this might impact SPY.
just back from overseas.
Listened to the recent presentation and would agree that when Arun was speaking of
50%,25% and 25%, he was discussing the state of affairs of the old lifecell customers.
Over the too many decades i have been investing in the medical industry, I have seen so many
companies in the current situation of Novadaq. They all reached a bridge they had to cross; namely, crossing over from a medical device developer to a medical device marketeer. It is oftentimes a difficult passage, particularly for the CEO, who's background is science and not business development.
I love this company's products from every perspective. Given the current size of the sales force, I am somewhat disappointed in revenue growth.
One last point for now. I have never owned another company like this where the institutional ownership has grown to such a level, while at the same time, so has the short interest. Both at record levels for the company.
You are right, those options expire on the March 29, 2015. That forces his hand. But he still had two weeks to go before expiry, so chartwise and locally, he determined to exercise on that date to optimize his trade taxwise.
Note that Rick Mangat has until March 29, 2015 to eercise his 16,322 options.
Both these guys bailed at about the same time when the stock was higher. So I would be paying attention to their trades!
The significance of this trade is that he thinks the bottom has been reached for this stock. This trade allows all future gains to be taxed as capital gains and it has minimized his options gains which are fully taxable. A cue to buy when the market steadies if you agree with his reason to exercise his options!
Can anyone here confirm a 20000 share sale by Dr. Menawat on 16MAR2015? This appeared at http://www.lulegacy.com/2015/03/16/novadaq-technologies-director-dr-arun-menawat-sells-20000-shares-ndq/
Agreed of course!
Still, if the small retail SHs got coordinated online and intervened abruptly,
wonder if we couldn't drive off the shorts?
The value of SPY is the key to my long term investment. Short term stock gyrations are less important . I bring up the short interest only as the icing on the cake.
Macular degeneration is is increasingly popular ( i'm on the possible future list there) with us boomers. Wonder why it failed?
The treatment options are not encouraging.
Musing...If the short interests communicate and gang up on the SP during quiet or negative times...does it follow that we small SHs could similarly save our investable bucks, wait for juicy news bits and then pile on all at once to spike the SP?
Last seen, lymph node tracing required injection of a radioactive tracer into the affected tissue ( breast for example, with a big, very long needle), and then sticking the patient under a radioactive substance scanner some time later.
To be able to do it in real time during surgery would;d be splendid.
During my own cancer surgery, they slit me from crotch to diaphragm, twisted my torso to open the zorro incision, put my guts in a tray, and dissected out each of the lymph nodes along my spine to send to the pathologist. They did a hell of a lot of damage along the way trying to find them. A more precise methodology would have been greatly appreciated.
I'm long here for a reason.
It'll do what it does regardless,till the new numbers come in, then they will be ignored.
When we finally book substantial profits for a few quarters...Things will change.
Giggle...Asking spammers for verification is an exercise in hollow futility.
They lie and try to sell and veracity has Nothing to do with it, as you know.
According to Nasdaq:
Settlement date as of March 13, 2015
short interest for nvdq is 4,741,244 shares(all time high)
Days to cover: 23
(based on average daily volume of 206,002)
Wonder if today's action reflects any elephants busting through the short covering door.
Thanks for the research. Having a group of fellows like you (I assume your a fellow, unless your from the south of the Mason-Dixon line...Ha, Ha) sharing and probing and questioning is both stimulating and helps solidify and verify my thoughts and modeling of Novadaq.
Before getting too excited, this may be a quietly discontinued product. There is a reference in the 2009 Q4 statement to a write down of the OPTTX intangible asset and inventory. Sorry if I didn't perform adequate DD before posting.
Good find Buzzy. I haven't heard anything and they don't break it out in their releases or talk about it. Perhaps someone should contact them.
1)What is the market potential
2)What is Novadaq's plan for penetrating this market
3)What would be the possible revenue per patient
4)Where are they on their plan
I was totally unaware that Novadaq makes a device (known as the OPTTX System, CE Mark 2006) to diagnose and treat age-related, wet Macular Degeneration. Evidently, the system combines SPY imaging technology and cauterization. Most web information about it from the 2005-2008 era, mostly trial and study references, but announcement information was from prnewswire. A term search of the company website with "optxx" or "macular" came up with zero hits.